CCM
CLLS

Chiron Capital Management’s Cellectis CLLS Stock Holding History

Chiron Capital Management’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-450
Closed -$8K – 144
2020
Q3 		$8K Buy
+450
New +$7.99K 0.01% 309

Other funds holding CLLS

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Chiron Capital Management's CLLS Position: Q4 2020 in Review

Chiron Capital Management sold out of Cellectis (CLLS) in Q4 2020, closing a stake of 450 shares — an estimated $8K sold.

Chiron Capital Management first reported a position in CLLS in Q3 2020 and held it in 1 quarter. The position peaked at $8K in Q3 2020. 90 funds tracked by Wall St. Rank hold CLLS as of Q4 2020.

  • Chiron Capital Management reported no remaining Cellectis position as of Q4 2020 after selling out during the quarter.
  • Chiron Capital Management sold 450 Cellectis shares in Q4 2020, an estimated $8K.
  • Chiron Capital Management first reported a position in Cellectis in Q3 2020 and held it in 1 quarter.
  • Chiron Capital Management's Cellectis position peaked at $8K in Q3 2020.
  • 90 funds tracked by Wall St. Rank held Cellectis as of Q4 2020.

Based on Chiron Capital Management's 13F filing for Q4 2020, filed 5 Mar 2021.